TY - JOUR
T1 - Treatment of viral infections with 5-aminolevulinic acid and light
AU - Smetana, Zehava
AU - Malik, Zvi
AU - Orenstein, Arie
AU - Mendelson, Ella
AU - Ben-Hur, Ehud
PY - 1997
Y1 - 1997
N2 - Background and Objective: When 5-aminolevulinic acid (ALA) is exogenously supplied, protoporphyrin IX (PpIX) is accumulated in various cells and makes them light sensitive. The possibility of using such an approach for the treatment of vital infections was studied in this work. Study Design/Materials and Methods: ALA was added to cultured cells infected with human immunodeficiency virus (HIV). Accumulation of PpIX in the cells as well as virus infectivity after photodynamic treatment (PDT) were assessed. For in vivo studies, guinea pigs were infected with herpes simplex virus (HSV) and then administered ALA at intervals after infection. The animals were exposed to PDT at the site of infection 3 hours after ALA administration. Clinical observations and virus titration were made daily. For clinical studies, two patients with Molluscum contagiosum and Verrucae vulgares were treated with ALA fortified with an iron chelating agent and dimethyl-sulfoxide, followed 4 hours later by PDT. Results: Cells that are infected with HIV accumulated PpIX upon addition of ALA in vitro. This accumulation was enhanced ~two-fold in the presence of an iron chelator. Subsequent exposure to red light PDT drastically reduced the virus titer (> 99% for U1 cells latently infected with HIV). In guinea pigs infected with HSV, subsequent administration of ALA and exposure of the lesions to red light shortened the duration of vesicles' appearance from more than a week to a few days and reduced HSV titer in the lesions by ≤ 5 log10. ALA-PDT treated AIDS patient suffering from Molluscum cotagiosum or a kidney transplant patient with Verrucae vulgares showed greatly improved clinical symptoms one month after treatment. Conclusion: It is concluded that ALA-PDT could be effective in treating certain viral infections, particularly those resulting in warts.
AB - Background and Objective: When 5-aminolevulinic acid (ALA) is exogenously supplied, protoporphyrin IX (PpIX) is accumulated in various cells and makes them light sensitive. The possibility of using such an approach for the treatment of vital infections was studied in this work. Study Design/Materials and Methods: ALA was added to cultured cells infected with human immunodeficiency virus (HIV). Accumulation of PpIX in the cells as well as virus infectivity after photodynamic treatment (PDT) were assessed. For in vivo studies, guinea pigs were infected with herpes simplex virus (HSV) and then administered ALA at intervals after infection. The animals were exposed to PDT at the site of infection 3 hours after ALA administration. Clinical observations and virus titration were made daily. For clinical studies, two patients with Molluscum contagiosum and Verrucae vulgares were treated with ALA fortified with an iron chelating agent and dimethyl-sulfoxide, followed 4 hours later by PDT. Results: Cells that are infected with HIV accumulated PpIX upon addition of ALA in vitro. This accumulation was enhanced ~two-fold in the presence of an iron chelator. Subsequent exposure to red light PDT drastically reduced the virus titer (> 99% for U1 cells latently infected with HIV). In guinea pigs infected with HSV, subsequent administration of ALA and exposure of the lesions to red light shortened the duration of vesicles' appearance from more than a week to a few days and reduced HSV titer in the lesions by ≤ 5 log10. ALA-PDT treated AIDS patient suffering from Molluscum cotagiosum or a kidney transplant patient with Verrucae vulgares showed greatly improved clinical symptoms one month after treatment. Conclusion: It is concluded that ALA-PDT could be effective in treating certain viral infections, particularly those resulting in warts.
KW - Herpes simplex virus
KW - Human immuno-deficiency virus
KW - Photodynamic treatment
KW - Virus inactivation
KW - Warts
UR - http://www.scopus.com/inward/record.url?scp=0030923478&partnerID=8YFLogxK
U2 - 10.1002/(SICI)1096-9101(1997)21:4<351::AID-LSM6>3.0.CO;2-P
DO - 10.1002/(SICI)1096-9101(1997)21:4<351::AID-LSM6>3.0.CO;2-P
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 9328982
AN - SCOPUS:0030923478
SN - 0196-8092
VL - 21
SP - 351
EP - 358
JO - Lasers in Surgery and Medicine
JF - Lasers in Surgery and Medicine
IS - 4
ER -